CClinicalTrials.gg
CompletedNCT04032457PAVESUpdated Oct 6, 2020

PAVES Benchmarking Pilot Study of Daily Disposable Contact Lenses

An interventional study of Phase A - olifilcon B with Tangible Coatings and Phase B - etafilcon A with Tangible Coatings in Refractive Errors, sponsored by Vision Service Plan. Completed at 6 sites in United States. Open to participants aged 18 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-06.

Sponsored by Vision Service Plan · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2019, 7 years 2 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
All
01

Study summary

The study will compare the short-term clinical performance and wearer and practitioner acceptability in a pilot study of a new-to-market spherical silicone hydrogel daily disposable soft contact lens (SiHyDD) to three (3) benchmark soft daily disposable lenses (DD) and, subsequently, of a new-to-market hydrogel spherical daily disposable (HydDD) soft contact lens to three (3) other hydrogel daily disposable lenses. .

The primary outcome variables for this study are subjective comfort and lens preference.

Read the detailed description

The objective of the study is to compare the short-term clinical performance and wearer and practitioner acceptability in a pilot study of a new-to-market spherical silicone hydrogel olifilcon B with Tangible Coating daily disposable soft contact lens (SiHyDD) to three (3) benchmark soft daily disposable lenses (DD) and, subsequently, of a new-to-market hydrogel etafilcon A with Tangible Coating spherical daily disposable (HydDD) soft contact lens to three (3) other hydrogel daily disposable lenses. .

The primary outcome variables for this study are subjective comfort and lens preference.

02

Conditions studied

  • Refractive Errors

Browse trials for

Keywords

  • Contact Lens
03

In context

Refractive Errors

413 studies on the registry are indexed under Refractive Errors; 62 are open to participants now.

This study's enrollment of 144 is above the median of 82 across 296 interventional studies indexed under Refractive Errors.

Browse Refractive Errors studies →

Lead sponsor

Vision Service Plan is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy full-time wearers of spherical daily disposable contact lenses
  • Vision correctable to 20/30 with spherical lenses in powers from +3.00 to +1.00 DS and from -1.00 to -7.00 DS
  • Visual acuity corrected to at least 20/30 with spherical contact lens

Exclusion criteria

Exclusion Criteria:

  • Participating in another clinical trial
  • Vision not correctable to 20/30 with lens powers listed above
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Care provider)
Enrollment
144 participants (actual)

Study arms

  • Active comparator
    A1 - SiHyDD to Moist

    1 week of Test SiHyDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.

    Device: Phase A - olifilcon B with Tangible Coatings

  • Active comparator
    A2 - Moist to SiHyDD

    1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.

    Device: Phase A - olifilcon B with Tangible Coatings

  • Active comparator
    A3 - SiHyDD to OASDD

    1 week of Test SiHyDD contact lenses followed by cross over to 1 week of ACUVUE® OASYS 1-Day contact lenses.

    Device: Phase A - olifilcon B with Tangible Coatings

  • Active comparator
    A4 - OASDD to SiHyDD

    1 week of ACUVUE® OASYS 1-Day contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.

    Device: Phase A - olifilcon B with Tangible Coatings

  • Active comparator
    A5 - SiHyDD to DT1

    1 week of Test SiHyDD contact lenses followed by cross over to 1 week of Alcon DAILIES TOTAL 1® contact lenses.

    Device: Phase A - olifilcon B with Tangible Coatings

  • Active comparator
    A6 - DT1 to SiHyDD

    1 week of Alcon DAILIES TOTAL 1® contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.

    Device: Phase A - olifilcon B with Tangible Coatings

  • Active comparator
    B1 - HydDD to Moist

    1 week of Test HydDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.

    Device: Phase B - etafilcon A with Tangible Coatings

  • Active comparator
    B2 - Moist to HydDD

    1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test HydDD contact lenses.

    Device: Phase B - etafilcon A with Tangible Coatings

  • Active comparator
    B3 - HydDD to BioTrue

    1 week of Test HydDD contact lenses followed by cross over to 1 week of BIOTRUE ONEday® contact lenses.

    Device: Phase B - etafilcon A with Tangible Coatings

  • Active comparator
    B4 - BioTrue to HydDD

    1 week of BIOTRUE ONEday® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.

    Device: Phase B - etafilcon A with Tangible Coatings

  • Active comparator
    B5 - HydDD to AqCom+

    1 week of Test HydDD contact lenses followed by cross over to 1 week of DAILIES® AquaComfort PLUS® contact lenses.

    Device: Phase B - etafilcon A with Tangible Coatings

  • Active comparator
    B6 - AqCom+ to HydDD

    1 week of DAILIES® AquaComfort PLUS® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.

    Device: Phase B - etafilcon A with Tangible Coatings

Interventions

  • DevicePhase A - olifilcon B with Tangible Coatings

    Daily disposable silicone hydrogel contact lens

  • DevicePhase B - etafilcon A with Tangible Coatings

    Daily disposable hydrogel contact lens

06

What researchers measure

Primary outcomes

  1. Subjective Lens Preference

    Subjective preference for either lens intervention or no preference. Likert question with forced preference for Test or Benchmark lens or no preference.

    Time frame: Visit 3 - Approximately 2 weeks

Secondary outcomes

  1. 8-item Contact Lens Dry Eye Questionnaire (CLDEQ-8) score

    Difference in CLDEQ-8 score with treatments relative to score with habitual lenses. The scale on the 8-item CLDEQ-8 instrument is from 1 to 33, with each item having a possible 4 or 5 points.

    Time frame: Visit 2 and 3 - Approximately 1 and 2 weeks, respectively

07

Study locations

6 sites
  • Ross Eyecare
    Atlanta, Georgia 30324, United States
  • Professional Eye Care Center
    Niles, Illinois 60714, United States
  • RevolutionEyes
    Carmel, Indiana 46032, United States
  • Andover Optometry on Central
    Andover, Massachusetts 01810, United States
  • Professional VisionCare
    Westerville, Ohio 43081, United States
  • Primary Eyecare Group, PC
    Brentwood, Tennessee 37027, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04032457
Lead sponsor
Vision Service Plan
Collaborators
Foresight Regulatory Strategies, Inc.
Responsible party
Sponsor
First posted
Jul 25, 2019
Start date
Mar 15, 2019
Primary completion
Aug 2, 2019
Completion
Aug 2, 2019
Last update
Oct 6, 2020

Study contacts

Robin L Chalmers, OD
principal investigator · Clinical Trial Consultant

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion